97 related articles for article (PubMed ID: 8084591)
1. p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis.
Saitoh S; Cunningham J; De Vries EM; McGovern RM; Schroeder JJ; Hartmann A; Blaszyk H; Wold LE; Schaid D; Sommer SS
Oncogene; 1994 Oct; 9(10):2869-75. PubMed ID: 8084591
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
3. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers.
Hartmann A; Blaszyk H; McGovern RM; Schroeder JJ; Cunningham J; De Vries EM; Kovach JS; Sommer SS
Oncogene; 1995 Feb; 10(4):681-8. PubMed ID: 7862445
[TBL] [Abstract][Full Text] [Related]
4. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
5. An abundance of p53 null mutations in ovarian carcinoma.
Skilling JS; Sood A; Niemann T; Lager DJ; Buller RE
Oncogene; 1996 Jul; 13(1):117-23. PubMed ID: 8700537
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA
Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204
[TBL] [Abstract][Full Text] [Related]
7. Molecular epidemiology of breast cancers in northern and southern Japan: the frequency, clustering, and patterns of p53 gene mutations differ among these two low-risk populations.
Blaszyk H; Hartmann A; Tamura Y; Saitoh S; Cunningham JM; McGovern RM; Schroeder JJ; Schaid DJ; Ii K; Monden Y; Morimoto T; Komaki K; Sasa M; Hirata K; Okazaki M; Kovach JS; Sommer SS
Oncogene; 1996 Nov; 13(10):2159-66. PubMed ID: 8950983
[TBL] [Abstract][Full Text] [Related]
8. High frequency of G/C transversion on p53 gene alterations in breast cancers from Taiwan.
Chen FM; Hou MF; Wang JY; Chen TC; Chen DC; Huang SY; Chung YS; Lin SR
Cancer Lett; 2004 Apr; 207(1):59-67. PubMed ID: 15050734
[TBL] [Abstract][Full Text] [Related]
9. Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma.
van Slooten HJ; van De Vijver MJ; Borresen AL; Eyfjörd JE; Valgardsdóttir R; Scherneck S; Nesland JM; Devilee P; Cornelisse CJ; van Dierendonck JH
J Pathol; 1999 Dec; 189(4):504-13. PubMed ID: 10629550
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
[TBL] [Abstract][Full Text] [Related]
11. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
Thorlacius S; Börresen AL; Eyfjörd JE
Cancer Res; 1993 Apr; 53(7):1637-41. PubMed ID: 8453635
[TBL] [Abstract][Full Text] [Related]
12. Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations.
McKenzie KE; Siva A; Maier S; Runnebaum IB; Seshadri R; Sukumar S
Clin Cancer Res; 1997 Sep; 3(9):1669-73. PubMed ID: 9815858
[TBL] [Abstract][Full Text] [Related]
13. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
14. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
15. Distant metastases in ovarian cancer: association with p53 mutations.
Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
[TBL] [Abstract][Full Text] [Related]
16. P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH.
Forslund A; Kressner U; Lönnroth C; Andersson M; Lindmark G; Lundholm K
Int J Oncol; 2002 Aug; 21(2):409-15. PubMed ID: 12118339
[TBL] [Abstract][Full Text] [Related]
17. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
18. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
19. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
[TBL] [Abstract][Full Text] [Related]
20. Pattern of p53 gene mutations in breast cancers of women of the midwestern United States.
Sommer SS; Cunningham J; McGovern RM; Saitoh S; Schroeder JJ; Wold LE; Kovach JS
J Natl Cancer Inst; 1992 Feb; 84(4):246-52. PubMed ID: 1734086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
